TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of ADHD combined subtype or predominantly hyperactive-impulsive subtype, based on psychiatric evaluation~* Capable of understanding and following classroom instructions~* Generally functioning academically at age-appropriate levels~Exclusion Criteria:~* ADHD, predominantly inattentive subtype~* Controlled or uncontrolled comorbid psychiatric diagnosis (except ODD) with significant symptoms such as PTSD, psychosis, bipolar disease, severe OCD, severe depressive or severe anxiety disorder~* Documented history of aggressive behavior serious enough to preclude participation in regular classroom activities~* Documented allergies or intolerance to either of the active treatments or tricyclic antidepressants

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Adderall XR (Type: EXPERIMENTAL): None
- Atomoxetine hydrochloride (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and non-pregnant, non-lactating women 45 years of age or older~* Able to give informed consent and complete scheduled visits~* Mild-moderate bilateral lower extremity peripheral arterial disease as defined by an ankle-brachial index (ABI measurement of 0.6-0.9. If a subject has baseline claudication symptoms, the symptoms must be stable for the 3 months preceding enrollment.~* History of hypertension. Blood pressure at the screening visit must be ≤160/100 mmHg and ≥100/60 mmHg for all subjects. If a subject is currently prescribed beta-blocker therapy, BP at the screening visit must be ≤140/90 mmHg. In addition, heart rate must be ≥55 beats per minute if currently prescribed a beta-blocker and ≤60 beats per minute if not currently prescribed a beta-blocker.~* At least moderate risk for CAD.~Exclusion Criteria:~* Participation in another clinical trial~* Ongoing ischemic (resting) limb pain, or lower extremity ulceration due to arterial insufficiency, or an ABI indicating \<0.6 indicating disease potentially requiring revascularization~* History of limb or digit amputation due to arterial insufficiency~* Revascularization of peripheral vessels within the preceding 6 months~* Uncontrolled hypertension as defined by systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg~* Contraindication or allergy to beta blocker therapy~* History of myocardial infarction , coronary revascularization, or a cerebrovascular event within the preceding 6 months~* Class III or IV angina~* Current or past history of New York Heart Association (NYHA) class III or IV heart failure~* Inability to walk on a treadmill for any reason~* Regular use of nitroglycerin or nitrates including oral, transdermal ointment or patch, or sublingual, translingual spray and/or combination agents containing nitrates~* Active liver, pulmonary, infectious or inflammatory process~* History of malignancy within preceding 5 years (excluding basal or squamous cell skin cancer)~* History of any other condition that, in the opinion of the investigators, renders it unsafe for the subject to be enrolled

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nebivolol (Type: EXPERIMENTAL): nebivolol 1 to 4 capsules daily
- metoprolol succinate (Type: ACTIVE_COMPARATOR): metoprolol 1 to 4 capsules daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female person aged 40 or older~* Subject with diagnosed lower limb ischemia (Fontaine-Pokrovsky Stages IIa-III of chronic limb ischemia)~* Signed informed consent~Exclusion Criteria:~* Any disease that can, in the opinion of the treating physician, affect the outcome of the study~* Patients with addictive disorders or substance abuse~* Pregnancy or nursing~* All other exclusion criteria listed in the summary of product characteristics (SmPC)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neovasculgen® (Type: EXPERIMENTAL): Single group prospective treatment
- standard care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Conversion to Monotherapy Study With Keppra XR for Partial Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects 12 to 75 years of age.~* Subjects must have inadequately controlled partial onset epilepsy.~* Subjects must be experiencing 2 to 40 seizures per 4-week period while being maintained on one or two standard AED(s)~Exclusion Criteria:~* A history of status epilepticus in the 6 months preceding randomization.~* Significant medical, psychiatric or neurological illness.~* Intake of benzodiazepines on more than an occasional basis~* History of previous treatment with levetiracetam or sensitivity to levetiracetam.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Keppra XR 1000 mg/day (Type: EXPERIMENTAL): 1000 mg/day once daily for 18 weeks (administered as two levetiracetam XR tablets and two placebo tablets once daily)
- Keppra XR 2000 mg/day (Type: EXPERIMENTAL): 2000 mg/day once daily for 18 weeks (administered as four levetiracetam XR tablets once daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced ovarian cancer with positive BRCA1 or BRCA2 status~* Failed at least one prior chemotherapy~* In investigators opinion, no curative standard therapy exists~* Measurable disease~Exclusion Criteria:~* Brain metastases~* Less than 28 days since last treatment used to treat the disease~* Considered a poor medical risk due to a serious uncontrolled disorder

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- KU-0059436 (AZD2281) 100 mg BID (Type: EXPERIMENTAL): None
- KU-0059436 (AZD2281) 400 mg BID (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* The participant completed the treatment period of a previous study of olipudase alfa with an acceptable safety profile in the opinion of the investigator and sponsor.~* The participant and/or the participant's parent(s)/legal guardian(s) was willing and able to provide signed written informed consent.~* The participant who is female and of childbearing potential must have had a negative urine pregnancy test for beta human chorionic gonadotropin (β HCG).~* Female participants of childbearing potential and sexually mature male participants must have been willing to practice true abstinence in line with their preferred and usual lifestyle or use 2 acceptable effective methods of contraception up to 15 days following their last dose of study drug.~Exclusion criteria:~* The participant had any new condition or worsening of an existing condition which in the opinion of the investigator would make the participant unsuitable for enrollment, or could interfere with the participation or completion the study.~* The participant, in the opinion of the investigator, was unable to adhere to the requirements of the study.~* The participant was unwilling or unable to abstain from the use of alcohol for 1 day prior to and 3 days after each olipudase alfa infusion for the duration of the treatment period.~* The participant was unwilling or unable to avoid, for 10 days before and 3 days after liver biopsies, medications or herbal supplements that are potentially hepatotoxic (only participants who previously participated in the DFI13412 study).~* The participant required medication(s) that may decrease olipudase alfa activity (eg, fluoxetine, chlorpromazine; tricyclic antidepressants \[eg, imipramine, desipramine\]).~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GZ402665 (Type: EXPERIMENTAL): GZ402665 administered intravenously once every 2 weeks at the dose each participant was receiving at the end of their previous olipudase alfa study, for 9 years or until olipudase alfa becomes commercially accessible, whichever comes first, unless the participant decides to enter another olipudase alfa clinical trial within the 9-year period prior to when olipudase alfa is commercially accessible.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inoperable estrogen receptor positive and HER2 negative breast cancer.~* Postmenopausal status.~* Tumor tissue (archived acceptable) available for biomarker studies. For Phase 2 Part 2 - CCND1 amplification and/or loss of p16 as determined by the central laboratory.~* Acceptable bone marrow, liver and kidney function.~Exclusion Criteria:~* Prior or concomitant treatment for advanced breast cancer.~* Other major cancer in the past 3 years.~* Important cardiovascular events in the past 6 months.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): letrozole + PD 0332991
- Arm B (Type: ACTIVE_COMPARATOR): letrozole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Preprocedural Diclofenac in Males Undergoing Double J Stent Removal Under Local Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All consecutive consenting male patients aged more than 18 years, undergoing DJ stent removal under local anesthesia (2% Lignocaine jelly) during the study period will be included.~Exclusion Criteria:~* Patients unable to understand visual analogue pain score~* Age \< 18 years~* Presence of Lower Urinary Tract Symptoms prior to surgery~* Presence of prostatitis or urethral stricture during cystoscopy~* Patients with renal failure (Serum creatinine \> 1.3 mg/dl)~* Patients on concomitant nephrotoxic drugs~* Patients with history of peptic ulcer or upper gastrointestinal bleed or upper abdominal surgeries~* Loss to follow up at 24 hours following DJ stent removal

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Diclofenac sodium (Type: EXPERIMENTAL): Oral diclofenac 75 mg one hour prior to stent removal
- Placebo (Type: PLACEBO_COMPARATOR): Placebo one hour prior to stent removal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PCOS based on the revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS (2003).~* All women were previously treated with 100 mg of CC daily for 5 days per cycle, for two to three cycles with persistent anovulation or ovulate with very thin endometrium \<5 mm at the time of hCG administration~Exclusion Criteria:~* patients with hyperprolactinaemia,~* hypercorticism and~* thyroid dysfunction.~* patients receiving medications as cholesterol lowering drugs, as statins, beta-blockers, and tricyclic antidepressants

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Coenzyme Q10/CC group (Type: EXPERIMENTAL): Intervention:~Coenzyme Q10 (CoQ10) and clomiphene citrate group (55 patients, 82 cycles) Patients in CoQ10/CC group took CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6, and CoQ10 Mepaco, Enshas Elraml, Sharkhia, Egypt), in a dose of 60 mg 3 times day capsules orally starting on cycle day 2 and continued till the day of human chorionic gonadotropin (hCG) administration
- CC alone group (Type: ACTIVE_COMPARATOR): Intervention:~CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women aged at least 18 years at time of Screening.~* Moderate to severe plaque-type psoriasis diagnosed for at least 3 months prior to Screening and candidate for systemic therapy.~* Other protocol defined inclusion criteria may apply. Please refer to the protocol.~Exclusion Criteria:~* Forms of psoriasis other than moderate to severe plaque-type psoriasis, e.g. drug-induced psoriasis at Screening.~* Patients with previous treatment with any agent targeting interleukin (IL)-17 directly or IL-17 receptor A (e.g. secukinumab, ixekizumab, or brodalumab).~* Pregnant or nursing (lactating) women~* Women of child-bearing potential unless they use effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): All patients are received s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during the first 4 weeks followed by monthly maintenance dosing of 300 mg secukinumab starting at Week 4 until Week 48. Consideration was given to discontinuing treatment in patients who showed no response up to 16 weeks of treatment (e.g. patients who did not achieve a PASI 50 response). If discontinued, patients completed the end of study visit assessments. Some patients with an initially partial response (e.g. patients who achieved a PASI 50 response but not a PASI 75 response) subsequently improved with continued treatment beyond 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria All Subjects~* Ability to provide Informed Consent/Assent~* 13 years of age or older~* Unilateral or bilateral user of a HiResolutionTM Bionic Ear System (HiRes 90KTM, HiRes 90KTM Advantage, HiResTM Ultra, HiResTM Ultra 3D)~* Minimum of 6 months of CI experience with a minimum of 1 month experience with a Naída CI or Sky CI sound processor~* At least moderate open-set speech recognition abilities (defined as speech in quiet score ≥ 60% as assessed at Visit 1)~* Minimum average score ≥ 3 on the Mobile Device Proficiency Questionnaire (MDPQ-16)~* English language proficiency as determined by the Investigator~* Willingness to use a BTE sound processor for the duration of the study~Inclusion Criteria Specific to Aidable Residual Hearing Group~* Residual low frequency hearing sensitivity (pure tone average of \< 70 dB HL for 125, 250, and 500 Hz) and a severe-to-profound high-frequency sensorineural hearing loss (pure tone average of ≥ 70 dB HL for 1,000, 2,000, 3000, 4,000, and 8,000 Hz) in the implanted ear for unilaterally implanted subjects and in both ears for bilaterally implanted subjects~* Willingness to use an in-canal acoustic earhook for the duration of the study~Exclusion Criteria:~* Clinical presentation indicative of potential implanted device malfunction~* Unrealistic expectations regarding potential benefits, risks and limitations of the investigational device as determined by the Investigator~* Unwillingness or inability of subject to comply with all investigational requirements as determined by the Investigator

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Electric Only (Type: OTHER): None
- Aidable Residual Hearing (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe idiopathic RLS with daytime symptoms~Exclusion Criteria:~* Females who are pregnant or lactating.~* Subjects with evidence of significant structural abnormalities of the gastrointestinal tract.~* Subjects with evidence of impaired liver/kidney function upon entry into the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OXN PR (Type: EXPERIMENTAL): Different daily doses; intake every 12 hours
- PLA (Type: PLACEBO_COMPARATOR): Different daily doses; intake every 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete